Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

CD40 agonists have been investigated as a strategy to awaken the immune system against cancers. Here, the authors use a virus encoding CD40L and tumour-associated antigens to enhance innate and adaptive immunity that together with tumour targeting antibodies controls the growth of tumours in mice.

Guardado en:

Detalles Bibliográficos
Autores principales:	José Medina-Echeverz, Maria Hinterberger, Marco Testori, Marlene Geiger, Raphael Giessel, Barbara Bathke, Ronny Kassub, Fabienne Gräbnitz, Giovanna Fiore, Sonia T. Wennier, Paul Chaplin, Mark Suter, Hubertus Hochrein, Henning Lauterbach
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/d593337aeba54d49978178381a7a20e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d593337aeba54d49978178381a7a20e5
record_format	dspace
spelling	oai:doaj.org-article:d593337aeba54d49978178381a7a20e52021-12-02T15:36:22ZSynergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies10.1038/s41467-019-12998-62041-1723https://doaj.org/article/d593337aeba54d49978178381a7a20e52019-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-12998-6https://doaj.org/toc/2041-1723CD40 agonists have been investigated as a strategy to awaken the immune system against cancers. Here, the authors use a virus encoding CD40L and tumour-associated antigens to enhance innate and adaptive immunity that together with tumour targeting antibodies controls the growth of tumours in mice.José Medina-EcheverzMaria HinterbergerMarco TestoriMarlene GeigerRaphael GiesselBarbara BathkeRonny KassubFabienne GräbnitzGiovanna FioreSonia T. WennierPaul ChaplinMark SuterHubertus HochreinHenning LauterbachNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q José Medina-Echeverz Maria Hinterberger Marco Testori Marlene Geiger Raphael Giessel Barbara Bathke Ronny Kassub Fabienne Gräbnitz Giovanna Fiore Sonia T. Wennier Paul Chaplin Mark Suter Hubertus Hochrein Henning Lauterbach Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
description	CD40 agonists have been investigated as a strategy to awaken the immune system against cancers. Here, the authors use a virus encoding CD40L and tumour-associated antigens to enhance innate and adaptive immunity that together with tumour targeting antibodies controls the growth of tumours in mice.
format	article
author	José Medina-Echeverz Maria Hinterberger Marco Testori Marlene Geiger Raphael Giessel Barbara Bathke Ronny Kassub Fabienne Gräbnitz Giovanna Fiore Sonia T. Wennier Paul Chaplin Mark Suter Hubertus Hochrein Henning Lauterbach
author_facet	José Medina-Echeverz Maria Hinterberger Marco Testori Marlene Geiger Raphael Giessel Barbara Bathke Ronny Kassub Fabienne Gräbnitz Giovanna Fiore Sonia T. Wennier Paul Chaplin Mark Suter Hubertus Hochrein Henning Lauterbach
author_sort	José Medina-Echeverz
title	Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
title_short	Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
title_full	Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
title_fullStr	Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
title_full_unstemmed	Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
title_sort	synergistic cancer immunotherapy combines mva-cd40l induced innate and adaptive immunity with tumor targeting antibodies
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/d593337aeba54d49978178381a7a20e5
work_keys_str_mv	AT josemedinaecheverz synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT mariahinterberger synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT marcotestori synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT marlenegeiger synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT raphaelgiessel synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT barbarabathke synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT ronnykassub synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT fabiennegrabnitz synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT giovannafiore synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT soniatwennier synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT paulchaplin synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT marksuter synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT hubertushochrein synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies AT henninglauterbach synergisticcancerimmunotherapycombinesmvacd40linducedinnateandadaptiveimmunitywithtumortargetingantibodies
_version_	1718386319403515904

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

Ejemplares similares